Rosai-Dorfman Disease involves histiocytic proliferation of the lymphatic system. Extranodal disease involving the central nervous system is uncommon. Furthermore, the combination of this disease entity with Langerhans cell histiocytosis is an even rarer phenomenon that has only recently been highlighted.
INTRODUCTION
Intracranial Rosai-Dorfman disease (RDD) is a rare, but well recognized clinical entity that needs to be differentiated from plasmacyte-rich meningiomas. Langerhans cell histiocytosis (LCH) is a more common disorder that frequently involves the skull bones. However, the combination of these two disorders occurring in the same patient is extremely rare. Of the 12 cases reported in literature (5, 15, 18, 21) , only one had both lesions occurring in the intracranial compartment (5) . We present a young male who developed calvarial LCH followed 2 years later by intracranial RDD in an adjacent location. The current literature and treatment options are reviewed.
CASE REPORT
A 31-year-old male of Asian origin presented with two episodes of focal motor seizures involving the right upper limb, with secondary generalization and post-ictal weakness of the right upper limb. He had earlier undergone a left frontal craniectomy and cranioplasty for an osteolytic skull lesion with a large extracranial component, which had been reported as LCH. This had been based on the typical appearance of the lesion on histopathology, with extensive histiocytic infiltration. An MRI of the brain with contrast showed a large, enhancing, dural based mass lesion in the left posterior frontal and parietal region with significant perilesional edema ( Figure  1 ). The dura surrounding the lesion was also enhancing with contrast, and the image characteristics were consistent with a radiological diagnosis of a meningioma. There was another small (1cm) lesion in the anterior frontal area, which was also enhancing with contrast.
He underwent a left parietal craniotomy and excision of the mass under general anesthesia. The dura was found to be diffusely thickened in all directions. The lesion was firm, grayish white in color and relatively avascular. It was totally excised along with the surrounding dura. During the immediate post operative period, he had slight worsening of power in the right upper limb, but this recovered within 3 weeks with physiotherapy.
Grossly, the cut sections of the tumor were grey-white and homogenous with no areas of necrosis. It also demonstrated a vague fibrous appearance. Microscopically, the sections showed sheets of spindle fibroblastic proliferation in whorls and fascicles with collections of inflammatory cells composed of histiocytes, lymphocytes and plasma cells ( Figure 2 ). There was no evidence of meningothelial nodules, but a spindle cell arrangement and histiocytic collections were noted ( Figure  3 ).
The initial differential diagnoses considered in our case were inflammatory myofibroblastic tumour, plasma cell rich meningioma and inflammatory histiocytic lesions versus Langerhans cell histiocytosis. Langerhans histiocytes with their folded nuclei and eosinophil infiltrates were conspicuously absent in the intracranial lesion, as against their presence in the osteolytic lesion that had been excised two years earlier.
With this background a panel of immunohistochemistry was done to reach the final diagnosis. EMA and PR were negative, and this along with the lack of typical meningothelial nodules even after examining the entire tissue ruled out the diagnosis of meningioma.
Alk1 was negative and the cells were positive for SMA and Vimentin, which ruled out the diagnosis of inflammatory myofibroblastic tumour. So also the further sections highlighted the sheets of histiocytes with emperipolesis (22) and lack of eosinophils, which were highly characteristic of RDD. Nodular lymphoid aggregates and plasma cell collections were seen. This along with S-100 protein and Ki-1 positivity clinched the diagnosis of Rosai-Dorfman disease.
He was referred to the Oncologist for further evaluation and management, as there was a small lesion in the frontal region which could also represent the same pathology.
DISCUSSION
Rosai-Dorfman disease (RDD) was first described by Lucien Destombes (6) (9) . RDD is an idiopathic histiocytic proliferation affecting lymph nodes, with extranodal involvement being reported in up to 43% of cases. Of these less than 5% show evidence of central nervous system and in 90% of these cases, the leptomeninges are afflicted (11) .
Over 50 patients with Rosai-Dorfman disease involving the CNS have been reported (3, 8, 19) . CNS Rosai-Dorfman disease shows a predilection for males, and typically presents during the 4th to 5th decade with the mean age of 39.4 years old (13) .
Histopathologically, a sheet like or interspersed pattern of lymphocytes and histiocytes, with the latter demonstrating emperipolesis, is characteristic of RDD. Occasional neutrophils and eosinophils may be seen and background fibrosis may be noted in extranodal disease. On immunohistochemical examination, histiocytes are immunoreactive for S-100 protein, HAM 56, α1 antitrypsin, α1 chymotrypsin, lysozyme, Mac 387 and Ki-1, but CD 1a and EMA are negative (2, 10, 16, 20) .
Our case was interesting because with the past history of LCH and the radiological features and gross morphology of a meningioma in the present lesion, the histopathology was critical in redefining the management plan. While a meningioma could have been followed up with serial imaging after total excision, a diagnosis of RDD meant that he would have to undergo chemotherapy to prevent recurrence.
Langerhans cell histiocytosis (LCH) is a rare disease of neoplastic proliferation of monocyte-macrophage system, resulting in abnormal accumulation of activated dendritic cells and macrophages, also known as histiocytes, in various tissues. Bones are commonly affected and unifocal disease (previously known as eosinophilic granuloma) may be mistaken for osteomyelitis or primary malignancy of the bone. The lesions are characterized by Langerhans cells which are bone marrow derived cells of dendritic cell line with antigen presenting and processing properties (1, 4, 12) .
RDD and LCH occurring in the same individual is an extremely rare occurrence, with only 12 reported cases in literature (5, 15, 18, 21) . In these patients, the lesions showed evidence of both diagnoses simultaneously, except in two cases. One patient presented as LCH initially and a recurrence 10 months later showed only RDD (15) . This was similar to our patient, who developed RDD two years after a diagnosis of bony LCH. The second case was undergoing chemotherapy for LCH, when he developed cutaneous papules that were diagnosed as RDD (21) . However, we believe that this is the first report in literature of the two lesions occurring in the skull and intracranial compartment. The co-occurrence of these two disease entities have led to the hypothesis that they may have comparable cytokine-mediated mechanisms or that both manifestations could be due to divergent differentiation from a common precursor, or that the histiocytes have undergone a phenotypic switch (15, 18) . The latter is particularly relevant when RDD follows LCH, where prior chemotherapy may have induced a change in the histiocytes.
While some patients have shown spontaneous resolution of the lesion, total surgical excision appears to be the treatment of choice in intracranial RDD, especially when the lesions produce mass effect. Where this is not possible, as in our case with diffuse infiltration of the dura, adjuvant chemotherapy, radiotherapy or prolonged steroid therapy may be useful in controlling the disease (7, 14) .
CONCLUSION
RDD and LCH occurring in the same patient is very rare but is being recognized more often with modern histopathological techniques. Though there are various postulates for this phenomenon, such as the two diseases representing different poles of the same spectrum or the Rosai-Dorfman disease being the result of chemotherapy induced changes in patients with LCH, the exact pathology can be elucidated only when more patients are available for detailed genomic studies.
